About Us

We are a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help people with cancer not only live longer, but live better. We aim to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being.

Our discovery process combines deep insights in clinically validated biological targets and differentiated chemistry with the goal of designing therapies for unmet needs. By combining clinically validated targets and specific target product profiles with disciplined clinical trial design and regulatory strategy, we aim to develop drugs with an increased probability of clinical success.

Learn more about our approach.

Our Team

We have assembled a team with significant expertise in drug discovery, development and commercialization with particular strengths in the discovery of small molecule kinase inhibitors. Our team includes:

  • World-renowned chemists who have been the primary or co-inventor of over 20 product candidates that have been advanced to clinical trials, including four FDA-approved cancer therapies: Koselugo (selumetinib), Mektovi (binimetinib), Tukysa (tucatinib), and Retevmo (selpercatinib).
  • Precision oncology and kinase inhibitor experts who have led or been involved with the discovery, development, or commercialization of over 60 small molecule kinase inhibitor programs, including Imbruvica (ibrutinib), Vitrakvi (larotrectinib), Zydelig (idelalisib), ipatasertib (AKT inhibitor), and PF-07284890/ARRY-461 (CNS-penetrant BRAF inhibitor).
  • Leaders with a track record of success who have built or led research, development and commercial operations at companies including AbbVie, Array BioPharma, Genentech, Biogen, Pharmacyclics, Five Prime Therapeutics-Amgen, Gilead Sciences, and Blueprint Medicines.
Sam_Kintz photo

Sam Kintz, MBA

Co-founder, Chief Executive Officer, and Member of the Board of Directors

Joe Lyssikatos photo

Joe Lyssikatos, PhD

Co-founder, Chief Scientific Officer

Anish Patel photo

Anish Patel, PharmD

Co-founder and Chief Operating Officer

Helen Collins photo

Helen Collins, MD

Chief Medical Officer

Ben Hohl photo

Ben Hohl

Chief Financial Officer and Head of Corporate Development

Galya Blachman photo

Galya Blachman, PhD, Esq

Chief Legal Officer and Head of Business Development

Board of Directors

Scientific Advisors